Presentation is loading. Please wait.

Presentation is loading. Please wait.

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1  Omar Abdel-Razek, MD, Singh N.

Similar presentations


Presentation on theme: "Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1  Omar Abdel-Razek, MD, Singh N."— Presentation transcript:

1 Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1  Omar Abdel-Razek, MD, Singh N. Sadananda, PhD, Xuan Li, MSc, Lubomira Cermakova, MSc, Jiri Frohlich, MD, FRCPC, Liam R. Brunham, MD, PhD, FRCPC  Journal of Clinical Lipidology  Volume 12, Issue 1, Pages (January 2018) DOI: /j.jacl Copyright © 2017 National Lipid Association Terms and Conditions

2 Figure 1 Prevalence of clinical or subclinical atherosclerotic cardiovascular disease (ASCVD) in individuals with damaging mutations in ABCA1 or APOA1. ∗P < .05. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

3 Figure 2 Cholesterol efflux capacity (CEC) in individuals with damaging mutations in ABCA1 or APOA1. (A) Cholesterol efflux capacity. Results are presented as mean ± standard deviation. (B) Correlation between cholesterol efflux capacity and HDL-C levels. (C) Correlation between cholesterol efflux capacity and apoA-I levels. ∗P < .05. HDL-C, high-density lipoprotein cholesterol. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions


Download ppt "Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1  Omar Abdel-Razek, MD, Singh N."

Similar presentations


Ads by Google